Zobrazeno 1 - 10
of 203
pro vyhledávání: '"Marshall M. Kaplan"'
Autor:
Andreas Meinhardt, Marshall M. Kaplan, Lin Leng, David J. Nikolic-Paterson, James L. Boyer, Richard Bucala, Melanie Merk, David N. Assis, Gerrit Grieb, Julius Chapiro, Yuka Mizue, Catherine H. McCrann, Jürgen Bernhagen, Clarence K. Zhang, Alvaro Baeza Garcia, Hongyu Zhao, Xin Du
Publikováno v:
Hepatology. 59:580-591
The role of the cytokine, macrophage migration inhibitory factor (MIF), and its receptor, CD74, was assessed in autoimmune hepatitis (AIH) and primary biliary cirrhosis (PBC). Two MIF promoter polymorphisms, a functional −794 CATT5-8 microsatellite
Autor:
Thomas P. Kenny, Richy C Y Chen, Jeffrey D. Butler, Kathryn G. Guggenheim, Patrick S.C. Leung, Ross L. Coppel, Christopher L. Bowlus, Min-Hua Tao, Shang-An Shu, Jinjun Wang, Aftab A Ansari, Guo-Xiang Yang, Phornnop Naiyanetr, Marshall M. Kaplan, Ana Lleo, Mark J. Kurth, M. Eric Gershwin
Publikováno v:
Hepatology. 57:1498-1508
Antimitochondrial antibodies (AMAs) directed against the lipoyl domain of the E2 subunit of pyruvate dehydrogenase (PDC-E2) are detected in 95% of patients with primary biliary cirrhosis (PBC) and are present before the onset of clinical disease. The
Publikováno v:
Clinical Gastroenterology and Hepatology. 9:609-612
Background & Aims The prevalence of and the most appropriate way to diagnose the primary biliary cirrhosis (PBC)–chronic autoimmune hepatitis (AIH) overlap syndrome are uncertain. We investigated the prevalence of PBC and AIH and their level of ove
Publikováno v:
Digestive Diseases and Sciences. 55:3207-3217
Approximately 35% of PBC patients have progressive disease despite treatment with UDCA. We offered treatment with methotrexate and colchicine to PBC patients who had not responded fully to UDCA, after at least 1 year of treatment. A total of 91 PBC p
Autor:
Marshall M. Kaplan, Lauren Dowling, Peter A Bonis, Kathleen Viveiros, Darlene Casey, James S. Davis, John Leung, Isi Obadan
Publikováno v:
Digestive Diseases and Sciences. 55:3218-3223
Most patients with autoimmune hepatitis (AIH) require long-term immunosuppressive therapy (IS). While it is well established that solid organ transplant recipients have a high risk of developing non-melanoma skin cancer (NMSC) as a result of immunosu
Autor:
Marshall M. Kaplan, Raoul Poupon, Keith D. Lindor, E. Jenny Heathcote, M. Eric Gershwin, Nora V. Bergasa
Publikováno v:
Diseases of the Gallbladder and Bile Ducts
PBC is a chronic cholestatic liver disease characterized by high-titer serum antimitochondrial autoantibodies (AMAs) and autoimmune-mediated destruction of small- and medium-sized intrahepatic bile ducts [1–3]. The first description of biliary cirr
Publikováno v:
Digestive Diseases and Sciences. 54:2242-2246
Modafinil may be a potentially effective treatment for primary biliary cirrhosis (PBC)-related fatigue. About 42 patients were given a 3-day trial of 100-200 mg modafinil. Response was defined as increased energy, decreased somnolence and sleep requi
Autor:
Kentaro Kikuchi, Marshall M. Kaplan, Aftab A. Ansari, Zhe-Xiong Lian, Susumu Ikehara, Hiroshi Miyakawa, Ross L. Coppel, M. Eric Gershwin, Guo-Xiang Yang
Publikováno v:
Gastroenterology. 128:304-312
Background & Aims: Sera from patients with primary biliary cirrhosis (PBC) are characterized by the presence of antimitochondrial antibodies and elevated levels of immunoglobulin (Ig) M. We hypothesized that the increase in serum IgM is the result of
Publikováno v:
Digestive Diseases and Sciences. 50:167-170
Publikováno v:
Hepatology. 39:915-923
Primary biliary cirrhosis frequently progresses despite treatment with ursodeoxycholic acid (UDCA), the only approved therapy. Previous studies suggested that colchicine and methotrexate may improve biochemical tests of liver function, symptoms, and